(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Unicycive Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast UNCY's revenue for 2025 to be $1,988,694,327, with the lowest UNCY revenue forecast at $219,545,291, and the highest UNCY revenue forecast at $5,247,373,724. On average, 3 Wall Street analysts forecast UNCY's revenue for 2026 to be $32,930,587,420, with the lowest UNCY revenue forecast at $4,752,793,671, and the highest UNCY revenue forecast at $60,031,161,690.
In 2027, UNCY is forecast to generate $84,264,257,320 in revenue, with the lowest revenue forecast at $48,729,404,353 and the highest revenue forecast at $137,324,373,490.